Picture EBD Group BioPharm America 2018 Boston Partnering 600x60px
Organisation › Details

Mologen (Group)

MOLOGEN AG, a German biopharmaceutical company with headquarters in Berlin specializes in the research and development of innovative medications on the basis of DNA structures. The activities focus on numerous product developments which are relevant to the immune system; on the one hand vaccines against infectious diseases and on the other hand cancer medications. MOLOGEN AG is globally one of the few biotechnology companies with well tolerated DNA-based cancer treatment in the clinical development phase. The stocks of MOLOGEN AG are listed in the Prime Standard of the German stock exchange (ISIN DE0006637200). *


Period Start 1997-01-01 existent
Products Industry BIOTECH
  Industry 2 MIDGE® technology (Mologen)
Persons Person Söhngen, Mariola (Mologen 201511–201810 CEO before Paion 2000–201510 CMO + Co-Founder LEFT 11/18)
  Person 2 Miller, Walter (Mologen 201604– CFO before Nuvisan Gmbh + Santhera Pharmaceuticals)
Region Region Berlin
  Country Germany
  Street 30 Fabeckstr.
  City 14195 Berlin
  Tel +49-30-841788-0
  Fax +49-30-841788-50
    Address record changed: 2008-12-07
Basic data Employees B: 11 to 50 (2017-06-30)
  Currency EUR
  Annual sales 74,000 (revenues (2016) 2016-12-31)
  Profit -21,003,000 (2016-12-31)
  Cash 14,200,000 (2016-12-31)
    * Document for �About Section�: Mologen AG. (7/10/12). "Press Release: Mologen AG Capital Increase. Proceeds of 22 Million EUR".
Record changed: 2017-08-15


Picture [LSF] – The Business Web Portal 600x80px

More documents for Mologen (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group BioPharm America 2018 Boston September 600x60px

» top